In recent trading session, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) saw 0.61 million shares changing hands at last check today with its beta currently measuring 0.26. Company’s recent per share price level of $36.25 trading at -$0.87 or -2.34% at last check today assigns it a market valuation of $3.43B. That most recent trading price of RARE’s stock is at a discount of -66.54% from its 52-week high price of $60.37 and is indicating a premium of 18.37% from its 52-week low price of $29.59. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.97 million shares which gives us an average trading volume of 1.01 million if we extend that period to 3-months.
For Ultragenyx Pharmaceutical Inc (RARE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.21. Splitting up the data highlights that, out of 16 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 14 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) trade information
Upright in the red during last session for losing -2.34%, in the last five days RARE remained trading in the red while hitting it’s week-highest on Friday, 06/27/25 when the stock touched $36.25 price level, adding 5.08% to its value on the day. Ultragenyx Pharmaceutical Inc’s shares saw a change of -9.03% in year-to-date performance and have moved -2.40% in past 5-day. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a performance of 5.53% in past 30-days. Number of shares sold short was 6.08 million shares which calculate 5.87 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 89.5 to the stock, which implies a rise of 59.5% to its recent value today. Analysts have been projecting 64 as a low price target for the stock while placing it at a high target of 115. It follows that stock’s current price would drop -76.55% in reaching the projected high whereas dropping to the targeted low would mean a loss of -76.55% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.45% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 18.09% while estimates for its earnings growth in next 5 years are of 65.13%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)’s Major holders
Insiders are in possession of 3.46% of company’s total shares while institution are holding 98.71 percent of that, with stock having share float percentage of 102.25%. Investors also watch the number of corporate investors in a company very closely, which is 98.71% institutions for Ultragenyx Pharmaceutical Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at RARE for having 9.78 million shares of worth $401.98 million. And as of 2024-06-30, it was holding 11.2964 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 5.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.4718 of outstanding shares, having a total worth of $230.3 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.78 shares of worth $100.76 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 2.19 shares on Mar 31, 2025 , making its stake of worth around $79.31 million in the company or a holder of 2.32% of company’s stock.
